Special Issue "Epigenetics of Pancreatic Cancer 2.0"

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: 31 July 2021.

Special Issue Editors

Dr. Martin E. Fernandez-Zapico
E-Mail Website
Guest Editor
Schulze Center for Novel Therapeutics, Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Interests: pancreatic cancer; tumor microenvironment; histone methylation; nuclear and chromatin organization
Special Issues and Collections in MDPI journals
Dr. Christopher Pin
E-Mail Website
Guest Editor
Division Head and Scientist, Genetics and Development, Children's Health Research InstituteAssociate Professor, Depts. of Paediatrics, Physiology and Pharmacology, and OncologySchulich School of Medicine and Dentistry, University of Western Ontario
Interests: epigenetic regulation of pancreatic development and disease; acinar-to-duct cell metaplasia; unfolded protein response; ER stress; acinar cell physiology
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the role of epigenetics in pancreatic cancer, a dismal disease predicted to be second cause of cancer death by 2030. This aggressive and rapidly disseminated epithelial neoplasm is highly resistant to conventional chemotherapeutic and radiation-based treatments. The past several decades of pancreatic cancer research have yielded a tremendous amount of knowledge about the genetics of tumor cells; however, this knowledge has not translated into significant clinical advances in treatment and prevention. These genetic-based drivers of pancreatic cancer have been well studied in the past three decades, but they do not account for all of the phenotypic and molecular alterations demonstrated by tumor cells. Pancreatic cancer initiation and progression are the result of a heterogeneous and dynamic combination of both genetic and epigenetic mechanisms. With the identification of epigenetic alterations seen in early pancreatic preneoplastic lesions through the development of pancreatic cancer, an inherent complexity is implied in epigenetic changes that occur in parallel to genetic alterations. This Special Issue will discuss the present knowledge in the field of pancreatic cancer epigenetics and will be composed of the following works:

(see published papers, planned papers, and the publication in the previous Special Issue "Epigenetics of Pancreatic Cancer")

Dr. Martin E. Fernandez-Zapico
Dr. Christopher Pin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

Open AccessEditorial
New Aspects of the Epigenetics of Pancreatic Carcinogenesis
Epigenomes 2020, 4(3), 18; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4030018 - 31 Aug 2020
Viewed by 1038
Abstract
Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic [...] Read more.
Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic nor environmental factors completely explain susceptibility or pathogenesis. Defining the links between genetic and environmental events represents an opportunity to understand the pathogenesis of pancreatic cancer. Epigenetics, the study of mitotically heritable changes in genome function without a change in nucleotide sequence, is an emerging field of research in pancreatic cancer. The main epigenetic mechanisms include DNA methylation, histone modifications and RNA interference, all of which are altered by changes to the environment. Epigenetic mechanisms are being investigated to clarify the underlying pathogenesis of pancreatic cancer including an increasing number of studies examining the role as possible diagnostic and prognostic biomarkers. These mechanisms also provide targets for promising new therapeutic approaches for this devastating malignancy. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer 2.0)

Review

Jump to: Editorial

Open AccessReview
Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update
Epigenomes 2021, 5(2), 8; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5020008 - 09 Apr 2021
Viewed by 344
Abstract
Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim [...] Read more.
Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer 2.0)
Back to TopTop